Akebia Therapeutics (AKBA) Other Working Capital Changes (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Other Working Capital Changes data on file, last reported at -$1.4 million in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$1.4 million, down 214.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $18000.0 (up 100.98% YoY), and the FY2025 annual result was $2.7 million, up 159.7% from the prior year.
• Other Working Capital Changes retreated to -$1.4 million in Q1 2026 per AKBA's latest filing, from $8.7 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $13.8 million in Q4 2022 and troughed at -$8.1 million in Q4 2023.
• A 5-year average of -$1.0 million and a median of -$2.5 million in 2024 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2022 and 2025: Other Working Capital Changes slumped 670.9% in 2022, then soared 340.06% in 2025.
• A 5-year view of Other Working Capital Changes shows it stood at $13.8 million in 2022, then plunged by 158.86% to -$8.1 million in 2023, then jumped by 124.4% to $2.0 million in 2024, then soared by 340.06% to $8.7 million in 2025, then slumped by 116.34% to -$1.4 million in 2026.
• Business Quant data shows AKBA's Other Working Capital Changes at -$1.4 million in Q1 2026, $8.7 million in Q4 2025, and -$3.4 million in Q3 2025.